Implitapide

CAS : 177469-96-4

Ref. 3D-CHA46996

Informations sur le produit

• Nom: Implitapide
• Synonymes: (2S)-2-cyclopentyl-2-{3-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]phenyl}-N-[(1R)-2-hydroxy-1-phenylethyl]ethanamide, (αS)-α-Cyclopentyl-4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]-N-[(1R)-2-hydroxy-1-phenylethyl]benzeneacetamide, Bay-13-9952, Benzeneacetamide, α-cyclopentyl-4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]-N-(2-hydroxy-1-phenylethyl)-, [R-(R*,S*)]-, Benzeneacetamide, α-cyclopentyl-4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]-N-[(1R)-2-hydroxy-1-phenylethyl]-, (αS)-
• CAS: 177469-96-4

Description

Implitapide is a drug that belongs to the group of statins. It is a prodrug that undergoes hydrolysis by hepatic lipase and soluble guanylate cyclase to form dodecanedioic acid and 2-hydroxy-4,5-dihydro-3(2H)-furanone. Implitapide inhibits cholesterol synthesis by inhibiting hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and reduces the size of atherosclerotic lesions in animal models. Clinical studies have shown that implitapide has been effective in reducing serum triglycerides, LDL cholesterol, apolipoprotein B, total cholesterol, and low density lipoprotein cholesterol as well as increasing HDL cholesterol levels. Implitapide may also inhibit protein synthesis by binding to the enzyme cholesteryl ester transfer protein. This interaction prevents the transfer of cholesteryl esters from HDL to other lipoprote

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 531.7 g/mol
• Formule: C₃₅H₃₇N₃O₂
• Degré de pureté: Min. 95%